Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014

Size: px
Start display at page:

Download "Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014"

Transcription

1 H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters 214

2 Table of Contents I. Introduction...2 II. CHASC Antimicrobial Utilization Reports...3 III. Executive Summary...5 IV. MCH Antimicrobial Utilization Reports...7 A. Total MCH Antimicrobial DDD and Expenditures.7 B. Emergency Department..11 C. Home Parenteral Therapy..14 D. Intensive Care Unit 17 E. Medical Day Ward...2 F. Medicine.23 G. Surgery...26 V. Glossary...29 Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 1

3 Covenant Health Antimicrobial Stewardship Report MCH July December 213 I. INTRODUCTION Antibiotics are among the most commonly prescribed medications in acute care centers (Figure 1), yet can result in unintended patient toxicities, selection of pathogenic organisms, such as C. difficile, and promotion of antibiotic resistance. Antimicrobial Stewardship is an interdisciplinary activity that promotes the optimization of antibiotic selection, dose, route and duration in order to improve patient clinical outcomes and safety, minimize antibiotic adverse effects and toxicity, decrease the selection of pathogenic organisms and reduce antibiotic resistance rates. An effective Antimicrobial Stewardship Program (ASP) has been demonstrated to achieve the above outcomes and as of 213, has been mandated as a Required Organizational Practice by Accreditation Canada. Evaluation of the program has been scheduled for October 214. The Covenant Health Antimicrobial Stewardship Committee (CHASC) was developed in 213 and has since implemented several initiatives. Summary of CHASC Initiatives: 1. Formulary Restriction and Preauthorization As of October 7, 213 a restricted antibiotic preauthorization form must be completed in order for continued dispensing of the following six restricted antibiotics: daptomycin, ertapenem, imipenem, linezolid, meropenem and tigecycline. The form ensures these antibiotics are being used in a guideline concordant manner and allows us to track their use for regular feedback and optimization of prescribing as necessary. These antibiotics were chosen because they are our six most broad and novel agents often serving as our last resort against multi-drug resistant (MDR) organisms, and should therefore be used only when necessary. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 2

4 2. Covenant Health Pocket Antibiogram In November 213, a pocket antibiogram was developed and distributed. The antibiogram informs prescribers about local resistance rates for common pathogens and assists in the selection of empiric antibiotics while awaiting culture and sensitivity data. 3. Prospective Audit and Feedback of Piperacillin-tazobactam In December 213, in response to persistently elevated piperacillin-tazobactam prescribing, the antibiotic stewardship pharmacists began auditing the use of this broad-spectrum antibiotic to ensure use was guideline concordant. 4. Development of a C. difficile (CDI) Preprinted Care Order (PPCO) with Prospective Audit and Feedback In December 213, CHASC in conjunction with the Covenant Health CDI Task Force developed a PPCO that standardizes and optimizes the management of CDI by ensuring prompt patient isolation, initiation of diagnostic tests and guideline concordant management. Additionally, the antimicrobial stewardship pharmacists audit medication use and attempt to discontinue unnecessary antibiotics or acid-suppressing agents, which are known to propagate CDI. 5. Collation of Antibiotic Utilization Data Collation of antibiotic utilization data will occur quarterly with distribution of reports and recommendations to stakeholders on a bi-annual basis. II. CHASC ANTIMICROBIAL UTILIZATION REPORTS Antibiotic use at Covenant Health acute care sites is collated and examined by CHASC on a quarterly basis in conjunction with data collected from prospective audit and feedback and the restricted antibiotic preauthorization form in order to: Identify any antibiotic utilization trends or areas in need of intervention on a site and service-specific basis. Ensure that the use of broad-spectrum antibiotics is guideline concordant. Generate bi-annual reports summarizing antibiotic trends and CHASC recommendations for prescribers as direct feedback on their antibiotic use. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 3

5 Methods Data on antibiotic use is extracted directly from Centricity (pharmacy computer system). When determining whether an antibiotic has been prescribed in a guideline-concordant fashion, clinical information acquired from the antibiotic preauthorization form and/or prospective audit and feedback performed by the Antimicrobial Stewardship pharmacists is compared to the provincial formulary recommendations. Drug utilization data is provided in both DDD (Defined Daily Dose) and expenditures and this first report details data for the period of July 1 to December 31, 213. DDD is a World Health Organization measure of drug consumption. The definition is the assumed average maintenance dose per day for a drug used for its main indication in adults. It relates all drug use to a standardized measure which is equivalent to one day s worth. DDD allows us to compare antibiotic use across different classes despite differences in potency and dosing. Examples: The usual dose of ertapenem is 1 g IV daily therefore every 1 gram of ertapenem is equivalent to one DDD. The usual dose of clindamycin is 6 mg IV every 8 hours therefore every 18 mg is equivalent to one DDD. In the near future, data will be presented as DDD/patient days to account for fluctuations in patient volume and therefore antibiotic prescribing. We are currently working closely with DIMR (Data integration, Measurement and Reporting) and Infection Prevention and Control to optimize the patient day denominator data prior to use. Summary of MCH Services included: Emergency Department Home Parenteral Therapy Intensive Care Unit Medical Day Ward (equivalent to an Intravenous therapy clinic) Medicine (Family, Geriatrics, Internal 3W, 4ALC, 4E, 7E, 7W) Surgery [Orthopedic, Other (General/Obstetrics & Gynecology/Urology) 5E, 5W, 6E, 6W, Surgical Day Ward] Antibiotic Groupings: Antibiotic utilization is provided in three graphical formats. 1. Total drug DDD and expenditures for the hospital and by service 2. Antibiotic classes as follows: Carbapenems - ertapenem, imipenem and meropenem Cefazolin Cephalosporins (3 rd generation) - ceftriaxone, ceftazidime and cefotaxime Clindamycin Fluoroquinolones - ciprofloxacin, levofloxacin and moxifloxacin Macrolides - azithromycin and erythromycin Piperacillin-tazobactam Vancomycin 3. Restricted antibiotics (daptomycin, ertapenem, imipenem, linezolid, meropenem and tigecycline) and piperacillin-tazobactam Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 4

6 III. Executive Summary Data on guideline concordance rates for the six restricted antibiotics (daptomycin, ertapenem, imipenem, linezolid, meropenem, and tigecycline) is available only from the time that the restricted antibiotic preauthorization form was implemented on October 7, 213. However, antibiotic utilization data is presented in this report from July to December 213 thereby capturing any trends in antibiotic utilization that could be attributed to the restricted antibiotic preauthorization form. Overall Antibiotic Use: Overall antibiotic use at MCH has remained stable during the period of July to December 213. Cephalosporins were the most frequently ordered IV antibiotic. Piperacillin-tazobactam use, although decreasing, remained high throughout the hospital. Restricted Antibiotics: Among the six restricted antibiotics, linezolid, meropenem and tigecycline have minimal usage. Although daptomycin use appeared higher than expected, the elevated DDD was attributed to a few patients that were deemed guideline concordant. Overall, use of the restricted antibiotics declined from October to December 213 with ertapenem being the most frequently ordered restricted antibiotic. In most instances, ertapenem was used appropriately (e.g. treatment of multi-drug resistant organisms); however, it was also being used in a guideline discordant manner for a few cases of surgical prophylaxis. Compliance with the Restricted Antibiotic Preauthorization Form and Formulary Concordance Rates: Since initiation of the restricted antibiotic preauthorization form on October 7, 213, compliance with form completion has been 81% and could be improved upon. The form is important as it: Ensures thorough data collection which is used to inform prescribers regarding extent of use and guideline concordance rates. Permits prospective audit and feedback by the Antimicrobial Stewardship committee if interventions in prescribing are required in real time. Is an effective strategy in an Antimicrobial Stewardship program and one of the tests for compliance during accreditation. Overall, prescribing of the six restricted antibiotics adhered to formulary guidelines in 59/72 (82%) of cases. Areas for improvement include surgical prophylaxis and empiric treatment of intra-abdominal infections (see surgery section of report). Recommendations: Continue to improve rates of compliance in filling out the restricted antibiotic preauthorization form Continue judicious use of the six restricted antibiotics by ensuring these broad-spectrum agents are only being used for formulary approved indications and are narrowed upon culture availability if possible. Antibiotic re-assessments should be performed hours after initiation and de-escalated according culture availability and the patient s clinical status. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 5

7 is not recommended for surgical prophylaxis. Ensure that ertapenem is used according to the below guidelines: 1. Empiric therapy of polymicrobial complicated skin and soft tissue infections, including bite wounds 2. Therapy of infections due to Enterobacteriaceae producing inducible (AmpC) β-lactamases or ESBLs where there is resistance to first line agents and documented susceptibility to ertapenem 3. Empiric therapy for patients at high risk (e.g. previous ESBL infection, international travel history) of infections due to Enterobacteriaceae producing ESBLs 4. Therapy of community-acquired intra-abdominal infections in patients intolerant or unresponsive to first line therapy (ceftriaxone + metronidazole) Piperacillin-tazobactam remains one of the most frequently prescribed antibiotics at MCH and will be the target of prospective audit and feedback by the Antimicrobial Stewardship pharmacists moving forward. Please ensure that piperacillin-tazobactam use adheres to the following formulary guidelines: Piperacillin-tazobactam 1. Empiric therapy of severe infections including sepsis of unknown source or suspected to be polymicrobial (eg. Intraabdominal, limb threatening diabetic foot) 2. Alone or in combination, empiric therapy of ventilator-associated pneumonia 3. Empiric therapy in high risk febrile neutropenic patients (oral temperature 38.3 C once or 38 C for 1 hour, absolute neutrophil count <.5 x 1 9 /L) +/- aminoglycoside NB: For monomicrobial infections due to Pseudomonas aeruginosa, options for therapy include ceftazidime, ciprofloxacin, piperacillin (still available), or aminoglycosides, according to susceptibility. Ensure surgical prophylaxis is administered in a guideline concordant manner thereby ensuring adequate coverage for the more likely pathogens while at the same time minimizing side effects and selection of resistance associated with broad-spectrum antibiotics. A summary of the recently updated surgical prophylaxis guidelines, developed by the Provincial Antibiotic Stewardship committee, is attached for your reference. Please refer to the service-specific section of this report for further details. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 6

8 IV. MCH Antimicrobial Utilization Reports A. Total MCH Antibiotic DDD and Expenditures July December 213 (Figure 2) Overall, parenteral antibiotics were ordered more frequently than oral and accounted for the vast majority of expenditures. Cephalosporins were the most commonly ordered IV antibiotic but carbapenems accounted for the majority of costs followed by piperacillin-tazobactam. The use of linezolid, meropenem and tigecycline was low. Daptomycin use was higher than expected but may be related to the large orthopedic population in the context of vancomycin allergies. was the most frequently prescribed restricted antibiotic although there was a trend towards decreased use from October to December 213. Piperacillin-tazobactam was the most frequently used broad-spectrum antibiotic although its use declined from August to December 213. Compliance with the restricted antibiotic preauthorization form was 81% (58/72) and could be improved upon (Table 1). Overall, the restricted antibiotics were used in a guideline concordant manner in 82% (59/72) of cases (Table 1). A portion of formulary discordant orders originated from pre-operative prophylaxis in the surgical services. Recommendations: Improve rates of form compliance to: o Ensure thorough and accurate data collection for feedback to prescribers. o Permit necessary prospective audit and feedback to improve appropriate use of the six restricted antibiotics. Antibiotic re-assessments should be performed hours after initiation and de-escalated according culture availability and the patient s clinical status. Improve ertapenem use and ensure that prescribing conforms to the below formulary guidelines: 1. Empiric therapy of polymicrobial complicated skin and soft tissue infections, including bite wounds 2. Therapy of infections due to Enterobacteriaceae producing inducible (AmpC) β-lactamases or ESBLs where there is resistance to first line agents and documented susceptibility to ertapenem 3. Empiric therapy for patients at high risk (e.g. previous ESBL infection, international travel history) of infections due to Enterobacteriaceae producing ESBLs 4. Therapy of community-acquired intra-abdominal infections in patients intolerant or unresponsive to first line therapy (ceftriaxone + metronidazole) Address piperacillin-tazobactam prescribing and ensure that this broad-spectrum antibiotic is being used according to the below formulary guidelines: Piperacillin-tazobactam 1. Empiric therapy of severe infections including sepsis of unknown source or suspected to be polymicrobial (eg. Intraabdominal, limb threatening diabetic foot) 2. Alone or in combination, empiric therapy of ventilator-associated pneumonia 3. Empiric therapy in high risk febrile neutropenic patients (oral temperature 38.3 C once or 38 C for 1 hour, absolute neutrophil count <.5 x 1 9 /L) +/- aminoglycoside NB: For monomicrobial infections due to Pseudomonas aeruginosa, options for therapy include ceftazidime, ciprofloxacin, piperacillin (still available), or aminoglycosides, according to susceptibility. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 7

9 Focus on antibiotic surgical prophylaxis to ensure that guideline concordant antibiotics are being administered. A summary of the recently updated surgical prophylaxis guidelines, developed by the Provincial Antibiotic Stewardship committee, is attached for your reference Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 8

10 Figure 2. MCH Total Antibiotic Usage and Expenditures MCH Total DDD MCH Total Expenditures Oral Parenteral $6 $5 $4 $3 $2 $1 $ Oral Parenteral MCH DDD Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $45 $4 $35 $3 $25 $2 $15 $1 $5 $ MCH Expenditures Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH DDD MCH Expenditures Daptomycin Imipenem Linezolid Meropenem Tigecycline $12 $1 $8 $6 $4 $2 $ Daptomycin Imipenem Linezolid Meropenem Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 9

11 Table 1. Total MCH Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Service Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) Ambulatory 9 9 (1%) 8 (89%) Total 9 9 (1%) 8 (89%) ER 6 6 (1%) 5 (83%) Imipenem 1 1 (1%) (%) Meropenem 2 2(1%) (%) Total 9 9 (1%) 5 (56%) HPT 1 1 (1%) 1 (1%) Total 1 1 (1%) 1 (1%) ICU 1 1 (1%) 1 (1%) Imipenem 4 4 (1%) 4 (1%) Meropenem 5 5 (1%) 5 (1%) Total 1 1 (1%) 1 (1%) Medicine 7 7 (1%) 6 (86%) Imipenem 6 5 (83%) 5 (83%) Linezolid PO 1 1 (1%) 1 (1%) Meropenem 4 3 (75%) 4 (1%) 1 (%) Total (89%) 16 (89%) Surgery Daptomycin 1 1 (1%) 1 (1%) 14 5 (36%) 9 (64%) 5 (1%) Imipenem 9 7 (78%) 7 (78%) Meropenem 1 1 (1%) 1 (1%) Total (56%) 18 (72%) Grand Total (82%) 58 (81%) 6 (83%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 1

12 B. MCH Emergency Department (ED) Antibiotic Utilization (Figure 3) Drug utilization data was recorded as ED prescribed if the patient resided in the ED at the time of dispensing. Once the patient had been transitioned to an inpatient ward or the MCH Medical Day Ward/IV clinic, the drug was thereafter recorded as prescribed from the new location. Therefore, if patients were admitted but remained in the ED for prolonged periods of time on antibiotics, ED utilization data would be affected. Overall, antibiotic usage and expenditures have remained stable in the ED. Oral and parenteral antibiotics were being ordered at relatively equal rates although parenteral antibiotics were responsible for the vast majority of antibiotic expenditures. The majority of orders were for cephalosporins. Piperacillin-tazobactam use remained high and serves as an area for potential examination and improvement to determine if its use is warranted or if there are more streamlined options that would be equally effective. The six restricted antibiotics were prescribed at low rates and have been guideline concordant from October 7 December 31, 213 (Table 2). Compliance with completing the restricted antibiotic preauthorization form has been adequate at 83% (Table 2). Recommendations: The ED has been effective in controlling their use of the six restricted antibiotics and ensuring they are used in a guideline concordant manner. No further recommendations can be made at this time. Improving completion rates of the restricted antibiotic preauthorization form is encouraged to allow for more accurate data collection to inform ED prescribing. Address piperacillin-tazobactam prescribing and ensure that this broad-spectrum antibiotic is being used according to the below provincial guidelines: Piperacillin-tazobactam 1. Empiric therapy of severe infections including sepsis of unknown source or suspected to be polymicrobial (eg. Intraabdominal, limb threatening diabetic foot) 2. Alone or in combination, empiric therapy of ventilator-associated pneumonia 3. Empiric therapy in high risk febrile neutropenic patients (oral temperature 38.3 C once or 38 C for 1 hour, absolute neutrophil count <.5 x 1 9 /L) +/- aminoglycoside NB: For monomicrobial infections due to Pseudomonas aeruginosa, options for therapy include ceftazidime, ciprofloxacin, piperacillin (still available), or aminoglycosides, according to susceptibility. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

13 Figure 3. MCH ED Antibiotic Usage and Expenditures MCH ED Total DDD MCH ED Total Expenditures 1 $5 8 $4 6 $3 4 Oral $2 Oral 2 Parenteral $1 Parenteral $ MCH ED DDD Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $4 $35 $3 $25 $2 $15 $1 $5 $ MCH ED Expenditures Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH ED DDD MCH ED Expenditures Daptomycin Imipenem Linezolid Meropenem Tigecycline $12 $1 $8 $6 $4 $2 $ Daptomycin Imipenem Linezolid Meropenem Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

14 Table 2. MCH ED Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) 6 6 (1%) 5 (83%) Imipenem 1 1 (1%) (%) Meropenem 2 2(1%) (%) Total 9 9 (1%) 5 (83%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

15 C. MCH Home Parenteral Therapy (HPT) Antibiotic Utilization (Figure 4) Home parenteral therapy enables patients to receive intravenous antibiotics at home. Patients can be enrolled in HPT through the Outpatient IV clinic or from an inpatient hospital unit at the time of discharge. Patients (or their drug coverage plan) are responsible for the cost of these antibiotics. HPT is often used when the duration of therapy is expected to be prolonged; therefore, overall patient numbers are low but due to these long courses of therapy, one patient can greatly influence the utilization of a particular antibiotic (e.g. one patient on ertapenem for 1 weeks results in an increased ertapenem DDD of 7). There were no identifiable trends in antibiotic use likely because the DDD and expenditures are greatly influenced by the number of patients in the program at any given time. Cefazolin was the most commonly prescribed antibiotic. Use of the six restricted antibiotics has been limited to a minority of patients; but due to long courses of therapy, has resulted in skewed graphs. For instance, although daptomycin use appeared high, its use was in one patient. Unfortunately, data on compliance with the restricted antibiotic preauthorization form and rates of guideline concordant use are lacking given the vast majority of patients were started on their restricted antibiotic as an inpatient or in the IV clinic and would therefore have been accounted for in that data set (Table 3). Recommendations: Prior to making recommendations, CHASC needs to reconcile HPT antibiotic use at the time of prescribing (e.g. on the ward or in the IV clinic) for better representation of guideline concordance rates. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

16 Figure 4. MCH HPT Antibiotic Usage and Expenditures MCH HPT Total DDD MCH HPT Total Expenditures* 1 $ Oral Parenteral $1 $8 $6 $4 $2 Oral Parenteral $ MCH HPT DDD MCH HPT Expenditures* Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $8 $7 $6 $5 $4 $3 $2 $1 $ Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH HPT DDD MCH HPT Expenditures* Daptomycin Imipenem Linezolid Meropenem Tigecycline $5 $4 $3 $2 $1 $ Daptomycin Imipenem Linezolid Meropenem Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. *Note: Patient responsible for costs Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

17 Table 3. MCH Home Parenteral Therapy Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) 1 1 (1%) 1 (1%) Total 1 1 (1%) 1 (1%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

18 D. MCH Intensive Care Unit (ICU) Antibiotic Utilization (Figure 5) MCH ICU drug utilization data pertains strictly to the Intensive Care Unit. Coronary care unit (CCU) data was collated separately but due to low antibiotic prescribing has not been incorporated into this specific report. If desired, please contact for CCU antibiotic utilization data. Overall antibiotic usage and expenditures have remained steady in the ICU. Carbapenem use has been increasing since October, despite becoming restricted antibiotics, and may relate to an increase in patient acuity as all orders were guideline concordant (Table 4). Compliance with the restricted antibiotic preauthorization form has been excellent at 1% (Table 4). Recommendations: Use of the restricted antibiotics is appropriate in the MCH ICU and no further recommendations are necessary at this time. Piperacillin-tazobactam use remains high. Given the relative acuity and complexity of these critically ill patients, whom often require broad-spectrum empiric therapy at the time of admission, it is suspected that the use of piperacillin-tazobactam is warranted. Antibiotic re-assessments should be performed hours after initiation and de-escalated according culture availability and the patient s clinical status. Further data acquired from ongoing prospective audit and feedback may shed further light on piperacillin-tazobactam use for future direction. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

19 Figure 5. MCH ICU Antibiotic Usage and Expenditures MCH ICU Total DDD MCH ICU Total Expenditures Oral Parenteral $8 $7 $6 $5 $4 $3 $2 $1 $ Oral Parenteral MCH ICU DDD MCH ICU Expenditures Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $45 $4 $35 $3 $25 $2 $15 $1 $5 $ Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH ICU DDD MCH ICU Expenditures Daptomycin Imipenem $2 $15 $1 Daptomycin Imipenem 2 1 Linezolid Meropenem Tigecycline $5 $ Linezolid Meropenem Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

20 Table 4. MCH ICU Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) 1 1 (1%) 1 (1%) Imipenem 4 4 (1%) 4 (1%) Meropenem 5 5 (1%) 5 (1%) Total 1 1 (1%) 1 (1%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

21 E. MCH Medical Day Ward/Outpatient IV clinic Antibiotic Utilization (Figure 6) The MCH Medical Day Ward functions as an IV clinic where patients attend to receive IV antibiotics when they are well enough to be treated as an outpatient and do not qualify for home parenteral therapy. Infectious diseases physicians and ED physicians are the main prescribers. Overall antibiotic use appeared to be trending down. The most frequently prescribed antibiotic was cefazolin although carbapenems made up the majority of the Medical Day Ward antibiotic expenditures. use decreased from October to December and all orders during that time frame have been guideline concordant (Table 5). Completion of the restricted antibiotic preauthorization form has been good at 89% (Table 5). Recommendations: Continue to ensure that ertapenem use is decreasing or stable and adheres to the provincial formulary as follows: 1. Empiric therapy of polymicrobial complicated skin and soft tissue infections, including bite wounds 2. Therapy of infections due to Enterobacteriaceae producing inducible (AmpC) β-lactamases or ESBLs where there is resistance to first line agents and documented susceptibility to ertapenem 3. Empiric therapy for patients at high risk (e.g. previous ESBL infection, international travel history) of infections due to Enterobacteriaceae producing ESBLs 4. Therapy of community acquired intra-abdominal infections in patients intolerant or unresponsive to first line therapy (ceftriaxone + metronidazole) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December 213 2

22 Figure 6. MCH Medical Day Ward/IV Clinic Antibiotic Usage and Expenditures MCH Medical Day Ward Total DDD MCH Medical Day Ward Total Expenditures Oral Parenteral $18 $16 $14 $12 $1 $8 $6 $4 $2 $ Oral Parenteral MCH Medical Day Ward DDD MCH Medical Day Ward Expenditures Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $1 $8 $6 $4 $2 $ Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH Medical Day Ward DDD MCH Medical Day Ward Expenditures Daptomycin Imipenem Linezolid Meropenem Tigecycline $9 $8 $7 $6 $5 $4 $3 $2 $1 $ Daptomycin Imipenem Linezolid Meropenem Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

23 Table 5. MCH Medical Day Ward/IV Clinic Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) 9 9 (1%) 8 (89%) Total 9 9 (1%) 8 (89%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

24 F. MCH Medicine Antibiotic Utilization (Figure 7) In this context, Medicine applies to Internal Medicine, Family Medicine (cannot be separated due to shared inpatient units) and Geriatrics. The data reported does not include the Internal Medicine unit that has temporarily been relocated to the Royal Alexandra Hospital. Overall, antibiotic utilization from July to December 213 has remained unchanged. Cephalosporins were the most commonly prescribed antibiotic. Piperacillin-tazobactam use has been increasing over time and should be an area of focus. The restricted antibiotics have been used in a guideline concordant manner in 89% of instances (Table 6). Compliance with completion of the restricted antibiotic preauthorization form has been good at 89% (Table 6). Recommendations: Continue to use the restricted antibiotics in a guideline concordant manner Antibiotic re-assessments should be performed hours after initiation and de-escalated according culture availability and the patient s clinical status. Usage of piperacillin-tazobactam has been increasing over the last six months and may be an area for improvement. Please ensure that piperacillin-tazobactam is being used according to the below formulary guidelines: Piperacillin-tazobactam 1. Empiric therapy of severe infections including sepsis of unknown source or suspected to be polymicrobial (eg. Intraabdominal, limb threatening diabetic foot) 2. Alone or in combination, empiric therapy of ventilator-associated pneumonia 3. Empiric therapy in high risk febrile neutropenic patients (oral temperature 38.3 C once or 38 C for 1 hour, absolute neutrophil count <.5 x 1 9 /L) +/- aminoglycoside NB: For monomicrobial infections due to Pseudomonas aeruginosa, options for therapy include ceftazidime, ciprofloxacin, piperacillin (still available), or aminoglycosides, according to susceptibility. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

25 Figure 7. MCH Medicine Antibiotic Usage and Expenditure MCH Medicine Total DDD MCH Medicine Total Expenditures Geriatrics Family & Internal Medicine Geriatrics Family & Internal Medicine MCH Medicine DDD MCH Medicine Expenditures Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $7 $6 $5 $4 $3 $2 $1 $ Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH Medicine DDD MCH Medicine Expenditures Daptomycin Imipenem Linezolid Meropenem $3 $25 $2 $15 $1 $5 Daptomycin Imipenem Linezolid Meropenem Tigecycline $ Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

26 Table 6. MCH Medicine Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) 7 7 (1%) 6 (86%) Imipenem 6 5 (83%) 5 (83%) Linezolid PO 1 1 (1%) 1 (1%) Meropenem 4 3 (75%) 4 (1%) 1 (%) Total (89%) 16 (89%) 1 (%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

27 G. MCH Surgery Antibiotic Utilization (Figure 8) Surgical data incorporates orthopedics, general surgery, obstetrics and gynecology, urology and surgical day ward. Overall, antibiotic use has remained stable during this time period with cephalosporins being the most commonly ordered IV antibiotic. Piperacillin-tazobactam use continued to remain high but has declined since August. Regarding the restricted antibiotics, although daptomycin use appeared atypically high, this order pertained to one patient where it was deemed guideline concordant. use spiked in October but has since come down. Unfortunately, from October 7 to December 31, 213, ertapenem was used in a guideline concordant manner in only 5/14 (38%) and should be an area of focus (Table 7). Compliance with completion of the restricted antibiotic preauthorization form has been reasonable at 72% and could be improved upon. Recommendations: Improve compliance with completion of the restricted antibiotic preauthorization form to ensure more accurate data collection and timely feedback for prescribers. Focus on pre-operative surgical prophylaxis and ensure that the antibiotic selected adheres to the provincial guidelines. o A summary of the recently updated surgical prophylaxis guidelines, developed by the Provincial Antibiotic Stewardship committee, is attached for your reference. Of note, only patients with an anaphylactic penicillin allergy or a severe cephalosporin allergy should avoid cefazolin. In these circumstances, alternatives would include clindamycin/gentamicin or vancomycin/gentamicin (refer to attached form). is unnecessarily broad and exposes the patient to more adverse effects and selection of resistance. Ensure that ertapenem is being used in a guideline concordant manner as per the below guidelines: 1. Empiric therapy of polymicrobial complicated skin and soft tissue infections, including bite wounds 2. Therapy of infections due to Enterobacteriaceae producing inducible (AmpC) β-lactamases or ESBLs where there is resistance to first line agents and documented susceptibility to ertapenem 3. Empiric therapy for patients at high risk (e.g. previous ESBL infection, international travel history) of infections due to Enterobacteriaceae producing ESBLs 4. Therapy of community acquired intra-abdominal infections in patients intolerant or unresponsive to first line therapy (ceftriaxone + metronidazole) Ensure that piperacillin-tazobactam use adheres to the below formulary recommendations: Piperacillin-tazobactam 1. Empiric therapy of severe infections including sepsis of unknown source or suspected to be polymicrobial (eg. Intraabdominal, limb threatening diabetic foot) 2. Alone or in combination, empiric therapy of ventilator-associated pneumonia 3. Empiric therapy in high risk febrile neutropenic patients (oral temperature 38.3 C once or 38 C for 1 hour, absolute neutrophil count <.5 x 1 9 /L) +/- aminoglycoside NB: For monomicrobial infections due to Pseudomonas aeruginosa, options for therapy include ceftazidime, ciprofloxacin, piperacillin (still available), or aminoglycosides, according to susceptibility. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

28 Figure 8. MCH Surgery Antibiotic Usage and Expenditures MCH Surgery Total DDD MCH Surgery Total Expenditures 3 $3 25 $25 2 $ Orthopedic Other $15 $1 $5 $ Orthopedic Other MCH Surgery DDD Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin $18 $16 $14 $12 $1 $8 $6 $4 $2 $ MCH Surgery Expenditures Carbapenems Cefazolin Cephalosporins 3rd generation Clindamycin Fluoroquinolones Macrolides Vancomycin MCH Surgery DDD MCH Surgery Expenditures Daptomycin Imipenem Linezolid Meropenem Tigecycline $8 $7 $6 $5 $4 $3 $2 $1 $ Daptomycin Imipenem Linezolid Meropenem Tigecycline DDD = Defined daily dose. Assumed average maintenance dose per day for a drug used for its main indication in adults. Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

29 Table 7. MCH Surgery Compliance with Preauthorization Form and Guideline Concordance Rates October 7 to December 31, 213 Restricted Antibiotic Number of orders Guideline concordant Form Compliance Recommendations (Number & Percent Accepted) Daptomycin 1 1 (1%) 1 (1%) 14 5 (36%) 9 (64%) 5 (1%) Imipenem 9 7 (78%) 7 (78%) Meropenem 1 1 (1%) 1 (1%) Total (56%) 18 (72%) 5 (1%) Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

30 V. Glossary of Terms ASP.Antimicrobial Stewardship Program CDI Clostridium difficile Infection CHASC... Covenant Health Antimicrobial Stewardship Committee DDD..Defined Daily Dose DIMR...Data integration, Measurement and Reporting ED...Emergency Department ESBL.....Extended spectrum beta-lactamase HPT..Home Parenteral Therapy ID... Infectious Diseases IMCU...Intermediate Care Unit MDR..Multi-drug resident MRSA. Methicillin resistant Staphylococcus aureus MSSA. Methicillin susceptible Staphylococcus aureus NB..Nota bene or Important, Note well NP Nurse Practitioner PAC...Pre-Admission Clinic PPCO.Preprinted Patient Care Order Prepared by the Covenant Health Antimicrobial Stewardship Committee (CHASC) for the period of July 213 December

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report to 214 Table of Contents I. Introduction..

More information

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 216 Table of Contents I. Introduction... 3 II. Executive Summary... 5 III. MCH Antimicrobial Utilization Reports...

More information

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report January June 215 Table of Contents I. Introduction... 3 II. CHASC Antimicrobial Utilization Reports... 4 III. Executive Summary...

More information

St. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report

St. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report St. Joseph s General Hospital Vegreville and Mary Immaculate Care Centre Antimicrobial Stewardship Report January to June 217 Introduction Antibiotics are among the most commonly prescribed medications

More information

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship July December 2017

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship July December 2017 Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship July December 217 Table of Contents Table of Contents... 2 I. Executive Summary... 3 II. GNCH Total Antimicrobial Utilization... 4 III. GNCH

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

Antimicrobial Stewardship Program: Local Experience

Antimicrobial Stewardship Program: Local Experience Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH

More information

Healthcare Facilities and Healthcare Professionals. Public

Healthcare Facilities and Healthcare Professionals. Public Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:

More information

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an

More information

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov

More information

Antimicrobial utilization: Capital Health Region, Alberta

Antimicrobial utilization: Capital Health Region, Alberta ANTIMICROBIAL STEWARDSHIP Antimicrobial utilization: Capital Health Region, Alberta Regionalization of health care services in Alberta began in 1994. In the Capital Health region, restructuring of seven

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

Jump Starting Antimicrobial Stewardship

Jump Starting Antimicrobial Stewardship Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Annual Report 216-217 Prepared by the Fraser Health Antimicrobial Stewardship Program June 217 Contents Executive Summary... 3 Background... 4 ASP Team Members... 5 Ackowledgements...

More information

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis

More information

Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim

Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Program/Project Description, including Goals What was the problem to be solved? How was it identified? What baseline data existed?

More information

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

Workplan on Antibiotic Usage Management

Workplan on Antibiotic Usage Management IMPACT Forum: Antibiotic Guideline in Perspective Workplan on Antibiotic Usage Management Dr. Raymond Yung Consultant Microbiologist PYNEH 20 April 2002 May 2002 Dr. Raymond Yung 1 Objective 1. Heighten

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

1. List three activities pharmacists can implement to support. 2. Identify potential barriers to implementing antimicrobial

1. List three activities pharmacists can implement to support. 2. Identify potential barriers to implementing antimicrobial OPTIMIZING ANTIMICROBIAL STEWARDSHIP: IT STARTS IN THE EMERGENCY DEPARTMENT! 1 2 Objectives 1. List three activities pharmacists can implement to support health-system antimicrobial stewardship programs

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Annual Report 2015-2016 Prepared by the Fraser Health Antimicrobial Stewardship Program August 2016 Contents Executive Summary... 3 Background... 4 ASP Team Members... 5 Ackowledgements...

More information

Antibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee

Antibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship at MetroWest Medical Center Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship Committee Subcommittee of Pharmacy and Therapeutics. Also

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities

Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we

More information

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects

More information

ANTIMICROBIAL STEWARDSHIP START SMART THEN FOCUS Guidance for Antimicrobial Stewardship for SHSCT

ANTIMICROBIAL STEWARDSHIP START SMART THEN FOCUS Guidance for Antimicrobial Stewardship for SHSCT ANTIMICROBIAL STEWARDSHIP START SMART THEN FOCUS Guidance for Antimicrobial Stewardship for SHSCT CLINICAL GUIDELINES ID TAG Title: Prepared by Specialty / Division: Directorate: Antimicrobial Stewardship

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Impact of Antimicrobial Stewardship Program

Impact of Antimicrobial Stewardship Program Impact of Antimicrobial Stewardship Program Ripal Joshi, Pharm.D. AAHIVP Tampa General Hospital January 28, 2016 Objectives Provide an overview on antimicrobial stewardship programs (ASP) Describe the

More information

Antimicrobial Stewardship Program 2 nd Quarter

Antimicrobial Stewardship Program 2 nd Quarter Antimicrobial Stewardship Program 2 nd Quarter May 19, 2016 Jill Hanson, WHA DeAnn Richards, MetaStar Objectives for Today Hospital Highlight UnityPoint Health - Meriter Status of the state Update on pilot

More information

Antimicrobial Stewardship. October 2012

Antimicrobial Stewardship. October 2012 Antimicrobial Stewardship October 2012 Rising Antimicrobial Resistance Methicillin resistant staphylococcus aureus (MRSA) Vancomycin resistant enterococci (VRE) MDR and extremely drug resistant (XDR TB)

More information

Promoting Appropriate Antimicrobial Prescribing in Secondary Care

Promoting Appropriate Antimicrobial Prescribing in Secondary Care Promoting Appropriate Antimicrobial Prescribing in Secondary Care Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2015 Introduction Background ESPAUR

More information

MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative

MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative Place picture here Nov. 14, 2017 Reminders For best sound quality, dial in at 1-800-791-2345 and enter code 11076 Please use the chat box to ask questions!

More information

Antibiotic Stewardship in the LTC Setting

Antibiotic Stewardship in the LTC Setting Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO

More information

Antimicrobial Stewardship Program

Antimicrobial Stewardship Program Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels

More information

Dr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College

Dr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and

More information

Healthcare-associated Infections and Antimicrobial Use Prevalence Survey

Healthcare-associated Infections and Antimicrobial Use Prevalence Survey Healthcare-associated Infections and Antimicrobial Use Prevalence Survey Shamima Sharmin, M.B.B.S., MSc, MPH Emerging Infections Program New Mexico Department of Health Agenda Recognize healthcare-associated

More information

Clinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24

Clinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24 Clinical Guideline District Infectious Diseases Management Sites where Clinical Guideline applies All facilities This Clinical Guideline applies to: 1. Adults Yes 2. Children up to 16 years Yes 3. Neonates

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Jump Start Stewardship

Jump Start Stewardship Jump Start Stewardship Webinar 2: Building your Stewardship Team and Selecting Interventions and Targets for your Implementation Welcome Thank you for your time today This webinar will be recorded for

More information

Measurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist

Measurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Measurement of Antimicrobial Drug Use Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Defined Daily Dose Target Audience: Administrators and Epidemiologists Standardized definition

More information

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic

More information

Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance

Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Natalie Weber, PharmD PGY2 Critical Care Pharmacy Resident September 22, 2016 The speaker has no actual or potential conflicts of

More information

IDENTIFICATION: PROCESS: Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital

IDENTIFICATION: PROCESS: Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital Organization Name: St. Joseph Medical Center Type: Acute Care Hospital Contact Person: Leigh Chapman RN,

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review (1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Antimicrobial Stewardship: A Matter of Process or Outcome?

Antimicrobial Stewardship: A Matter of Process or Outcome? Antimicrobial Stewardship: A Matter of Process or Outcome? Tina M. Khadem, Pharm.D., Elizabeth Dodds Ashley, Pharm.D., M.H.S., Mark J. Wrobel, Pharm.D., and Jack Brown, Pharm.D., M.S. The risk of antimicrobial

More information

ANTIBIOTIC STEWARDSHIP

ANTIBIOTIC STEWARDSHIP ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.

More information

Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India

Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Human Journals Research Article April 2016 Vol.:6, Issue:1 All rights are reserved by Zarine Khety et al. Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Keywords: Drug

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

Antimicrobial Stewardship:

Antimicrobial Stewardship: Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of

More information

Today s webinar will begin in a few minutes.

Today s webinar will begin in a few minutes. Today s webinar will begin in a few minutes. Please press *6 to mute your line or use the mute button on your phone. If you have questions for the presenter or need to contact TCPS staff, type your comments

More information

Antibiotic Stewardship in the Hospital Setting

Antibiotic Stewardship in the Hospital Setting Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship

More information

Best Practices: Goals of Antimicrobial Stewardship

Best Practices: Goals of Antimicrobial Stewardship Best Practices: Goals of Antimicrobial Stewardship Gail Scully, M.D, M.P.H. and Elizabeth Radigan, PharmD, BCPS UMass Memorial Medical Center Division of Infectious Disease Department of Medicine September

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

ANTIBIOTIC STEWARDSHIP. Brian Mayhue, Pharm D, CGP Director of Pharmacy Palm Beach Gardens Medical Center

ANTIBIOTIC STEWARDSHIP. Brian Mayhue, Pharm D, CGP Director of Pharmacy Palm Beach Gardens Medical Center ANTIBIOTIC STEWARDSHIP Brian Mayhue, Pharm D, CGP Director of Pharmacy Palm Beach Gardens Medical Center Antibiotic Resistance It is not difficult to make microbes resistant to penicillin in the laboratory

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required

More information

ANTIMICROBIAL STEWARDSHIP PROGRAM ANNUAL REPORT How you want to be treated.

ANTIMICROBIAL STEWARDSHIP PROGRAM ANNUAL REPORT How you want to be treated. ANTIMICROBIAL STEWARDSHIP PROGRAM ANNUAL REPORT 2016-17 How you want to be treated. Table of Contents Executive Summary Background Team Clinical Activities Financials Appendix Return to Table of Contents

More information

Effectiv. q3) Purpose of Policy. Pharmacy: Antimicrobial subcommp&tittee of

Effectiv. q3) Purpose of Policy. Pharmacy: Antimicrobial subcommp&tittee of Name ofpolicynupolicy:mber: Department: Approving Officer: Responsible Agent: Scope: Protected Antimicrobials 3364-133-106 Pharmacy: Antimicrobial subcommp&tittee of Chief Executive Officer Director of

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

This survey was sent only to EIN members with a pediatric infectious diseases practice.

This survey was sent only to EIN members with a pediatric infectious diseases practice. Infectious Diseases Society of America Emerging Infections Network Report for Query: Pediatric Outpatient Parenteral Antibiotic Therapy (OPAT) Overall response rate: 188/281 (66.9%) physicians responded

More information

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings

More information

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Updates in Antimicrobial Stewardship

Updates in Antimicrobial Stewardship Updates in Antimicrobial Stewardship Andrew Hunter, Pharm.D., BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center andrew.hunter@va.gov Disclosures No disclosures

More information

Using Data to Track Antibiotic Use and Outcomes

Using Data to Track Antibiotic Use and Outcomes Using Data to Track Antibiotic Use and Outcomes Michelle Nemec, PharmD Thrifty White Drug Pharmacy Objectives Describe the Antibiotic Stewardship Core Element of tracking and the specific interventions

More information

Why Antimicrobial Stewardship?

Why Antimicrobial Stewardship? Antimicrobial Stewardship: Why and How CAPT Arjun Srinivasan, MD Associate Director for Healthcare Associated Infection Prevention Programs Division of Healthcare Quality Promotion Why Antimicrobial Stewardship?

More information

National Antimicrobial Prescribing Survey

National Antimicrobial Prescribing Survey Indication documented Surgical prophylaxis >24 hrs Allergy mismatch Microbiology mismatch Incorrect route Incorrect dose/frequency Incorrect duration Therapeutic Guidelines Local guidelines * Non-compliant

More information

An audit of the quality of antimicrobial prescribing

An audit of the quality of antimicrobial prescribing An audit of the quality of antimicrobial prescribing Rakhee Patel, Antimicrobial Pharmacist Alison Williams, Antimicrobial Technician & Dr Armando Gonzalez-Ruiz May 2011 ICE Score 2 Introduction & Aims

More information

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience. Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial

More information

Provincial Drugs & Therapeutics Committee Memorandum Version 2

Provincial Drugs & Therapeutics Committee Memorandum Version 2 Provincial Drugs & Therapeutics Committee Memorandum Version 2 16 Garfield Street 16, rue Garfield PO Box 2000, Charlottetown C.P. 2000, Charlottetown Prince Edward Island Île-du-Prince-Édouard Canada

More information

Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults

Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults COMMUNITY-ACQUIRED PNEUMONIA HEALTHCARE-ASSOCIATED PNEUMONIA INTRA-ABDOMINAL INFECTION

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety

More information

ANTIBIOTICS IN THE ER:

ANTIBIOTICS IN THE ER: ANTIBIOTICS IN THE ER: EXPLORING THE ROLE OF ANTIMICROBIAL STEWARDSHIP IN THE EMERGENCY DEPARTMENT ANGELINA DAVIS, PHARMD, MS, BCPS (AQ-ID) LIAISON CLINICAL PHARMACIST DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH

More information

Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts

Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts Investigational Team: Diane Brideau-Laughlin BSc(Pharm),

More information

The Inpatient Management of Febrile Neutropenia

The Inpatient Management of Febrile Neutropenia UCSF Medical Center Adult Blood and Marrow Transplant Program 400 Parnassus Avenue, San Francisco, CA 94143 SOP # CL 120.05 The Inpatient Management of Febrile Neutropenia BACKGROUND: Neutropenia results

More information

Intro Who should read this document 2 Key practice points 2 Background 2

Intro Who should read this document 2 Key practice points 2 Background 2 Antibiotic Guidelines: Obstetric Anti-Infective Prescribing Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Kelly Alexander / Frances Garraghan

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Ready to Launch: Antimicrobial Stewardship for All!

Ready to Launch: Antimicrobial Stewardship for All! Ready to Launch: Antimicrobial Stewardship for All! Lucas Schulz, PharmD, BCPS AQ ID Clinical Coordinator Infectious Diseases PGY2 Infectious Diseases Residency Program Director Disclosures Consultant

More information

2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea

2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea 2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea Submitted by: Asia Pacific Foundation for Infectious Diseases Policy Forum on Strengthening Surveillance and Laboratory Capacity to

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP

It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings. Emily Heil, PharmD, BCPS-AQ ID, AAHIVP It s Time to Regulate Antimicrobial Stewardship Standards in Acute Care Settings Emily Heil, PharmD, BCPS-AQ ID, AAHIVP Conflict of Interest I have no conflicts of interest to disclose related to the content

More information